Recently, in a large retrospective study including NSCLC in treatment with immunotherapy, lymph node metastases were associated with the best response, lung and pleura metastases were associated with an intermediate response, and liver, which expressed TDO at high levels, and bone metastases were associated with the least responses to immunotherapy (38). Here, TDO2 is linked to non-small cell lung carcinoma.